The impact of age in Ph+ and Ph-like ALL
In this video, Robin Fo, MD, from the University of Rome, Rome, Italy, discusses the impact of age on patients with Ph+ or Ph-like acute lymphoblastic leukemia (ALL). This video was recorded at the 2...
Author: VJHemOnc
Added: 08/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The challenges halting clinical trial progress in ALL
Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, raises the issue of slow progression of clinical trials in acute lymphoblastic leukemia (ALL) and the factors that play a part. Speakin...
Author: VJHemOnc
Added: 08/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 24, 2018 Category: Cancer & Oncology Source Type: podcasts
NGS and high sensitivity ddPCR for detecting MRD
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, gives an ove...
Author: VJHemOnc
Added: 08/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The potential for a chemotherapy-free strategy in ALL
Here, Robin Fo, MD, from the University of Rome, Rome, Italy, discusses the potential of a chemotherapy-free strategy for patients with acute lymphoblastic leukemia (ALL). Speaking from the 2018 Euro...
Author: VJHemOnc
Added: 08/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Clinical approaches in Ph+ and Ph-like ALL
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Robin Fo, MD, from the University of Rome, Rome, Italy, talks about the clin...
Author: VJHemOnc
Added: 08/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Key areas of leukemia research
Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, points to the need for improving the methodology of measurable residual disease (MRD) testing in acute lymphoblastic leukemia (ALL). Pr...
Author: VJHemOnc
Added: 08/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 24, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD to determine risk of relapse after induction in AML
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of measurable residual disease (MRD) in acute myeloid leukemia (AML). Prof. Craddoc...
Author: VJHemOnc
Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Measurable residual disease in AML
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the use of measurable residual disease (MRD) in acute myeloid leukemia (AML). Prof. Burnett highlights its utility as an independe...
Author: VJHemOnc
Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Targeted vs. broader agents for maintenance in AML
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of targeted vs. broader agents in acute myeloid leukemia (AML). This interview was ...
Author: VJHemOnc
Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Gemtuzumab ozogamicin for AML: challenges and reapproval
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the antibody-drug conjugate gemtuzumab ozogamicin for acute myeloid leukemia (AML). Prof. Burnett covers the history of this drug,...
Author: VJHemOnc
Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Maintenance therapy strategies to reduce relapse in AML
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmin...
Author: VJHemOnc
Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Improving outcomes after transplant in AML
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses how we can improve outcomes after transplant in acute myeloid leukemia (AML). Prof. Craddoc...
Author: VJHemOnc
Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Challenges for access to CAR T-cell therapy
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany sta...
Author: VJHemOnc
Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Advice about ALL treatment in the clinical setting
In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, reflects on the differences between the treatment of acute lymphoblastic leukemia (ALL) in clinical practi...
Author: VJHemOnc
Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts
How have leukemia diagnostics and management evolved?
Elizabeth Macintyre, MD, PhD, of the Hpital Necker-Enfants Malades, Paris, France, speaks about the advances made in leukemia diagnostics and therapeutics from the 2018 European School of Hematology ...
Author: VJHemOnc
Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts
